Precision BioSciences Net Income 2018-2021 | DTIL

Precision BioSciences net income from 2018 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Precision BioSciences Annual Net Income
(Millions of US $)
2020 $-109
2019 $-93
2018 $-46
2017 $-21
Precision BioSciences Quarterly Net Income
(Millions of US $)
2021-09-30 $-11
2021-06-30 $22
2021-03-31 $-19
2020-12-31 $-23
2020-09-30 $-26
2020-06-30 $-33
2020-03-31 $-27
2019-12-31 $-21
2019-09-30 $-21
2019-06-30 $-19
2019-03-31 $-32
2018-12-31 $-15
2018-09-30 $-10
2018-06-30 $-12
2018-03-31 $-9
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.361B $0.024B
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69